SELLAS Life Sciences (SLS) Operating Income Growth (3y) (2014 - 2026)
SELLAS Life Sciences (SLS) Operating Income Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | 16.96% |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.65 Bn | 466.85 Bn | 1.35 Bn | 38.78% |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn | 13.47% |
| 6 | Regeneron Pharmaceuticals | 69.85 Bn | 61.09 Bn | 3.31 Bn | -12.10% |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.74 Bn | 50.56 Bn | 1.41 Bn | 69.02% |
| 9 | Revolution Medicines | 37.48 Bn | 37.48 Bn | - | - |
| 10 | SELLAS Life Sciences | 1.88 Bn | 1.78 Bn | - | 6.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.40% |
| Dec 31, 2025 | 4.39% |
| Sep 30, 2025 | 0.29% |
| Jun 30, 2025 | 7.28% |
| Mar 31, 2025 | 28.71% |
| Dec 31, 2024 | 15.87% |
| Sep 30, 2024 | -1.65% |
| Jun 30, 2024 | -19.62% |
| Mar 31, 2024 | -62.57% |
| Dec 31, 2023 | -25.28% |
| Sep 30, 2023 | -27.73% |
| Jun 30, 2023 | -28.48% |
| Mar 31, 2023 | -40.54% |
| Dec 31, 2020 | 21.44% |
| Sep 30, 2020 | -0.22% |
| Jun 30, 2020 | 4.58% |
| Mar 31, 2020 | 7.22% |
| Dec 31, 2017 | 3.99% |
| Sep 30, 2017 | 24.98% |
| Jun 30, 2017 | 32.24% |